Search research articles
Contact Us
Filters
Showing results (311-320 of 424) with videos related to
Page
of 43
Sort By:
The Journal of Surgical Research
|
April 1, 1985
A possible beneficial effect of metronidazole in reducing TPN-associated liver function derangements
H R Freund, M Muggia-Sullam, R LaFrance, et al.
Environmental Health Perspectives
|
November 1, 1992
Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro
M Dabholkar, L Bradshaw, R J Parker, et al.
Carcinogenesis
|
July 1, 1991
Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry
R J Parker, I Gill, R Tarone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 1998
Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumors
A A Garcia, S Keren-Rosenberg, D Parimoo, et al.
Cancer Treatment Reports
|
February 1, 1986
Activity of epirubicin in pancreatic carcinoma
H Hochster, M D Green, J L Speyer, et al.
Seminars in Oncology
|
August 1, 1995
Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials
F M Muggia, D Vafai, R Natale, et al.
European Journal of Cancer
|
February 1, 1981
Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute
A Goldin, J M Venditti, J S Macdonald, et al.
Cancer Investigation
|
January 1, 1995
Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma
M Turrill, D V Spicer, A S Kelley, et al.
American Journal of Clinical Oncology
|
October 1, 1985
A phase II study of bisantrene in advanced refractory breast cancer. An Eastern Cooperative Oncology Group pilot study
K J Pandya, F M Muggia, R T Skeel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 5, 2003
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions
A Chanan-Khan, J Szebeni, S Savay, et al.
Page
of 43
Search research articles
Search
Showing results (311-320 of 424) with videos related to
Sort By:
Page
of 43
The Journal of Surgical Research
|
April 1, 1985
A possible beneficial effect of metronidazole in reducing TPN-associated liver function derangements
H R Freund, M Muggia-Sullam, R LaFrance, et al.
Environmental Health Perspectives
|
November 1, 1992
Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro
M Dabholkar, L Bradshaw, R J Parker, et al.
Carcinogenesis
|
July 1, 1991
Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry
R J Parker, I Gill, R Tarone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 1998
Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumors
A A Garcia, S Keren-Rosenberg, D Parimoo, et al.
Cancer Treatment Reports
|
February 1, 1986
Activity of epirubicin in pancreatic carcinoma
H Hochster, M D Green, J L Speyer, et al.
Seminars in Oncology
|
August 1, 1995
Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials
F M Muggia, D Vafai, R Natale, et al.
European Journal of Cancer
|
February 1, 1981
Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute
A Goldin, J M Venditti, J S Macdonald, et al.
Cancer Investigation
|
January 1, 1995
Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma
M Turrill, D V Spicer, A S Kelley, et al.
American Journal of Clinical Oncology
|
October 1, 1985
A phase II study of bisantrene in advanced refractory breast cancer. An Eastern Cooperative Oncology Group pilot study
K J Pandya, F M Muggia, R T Skeel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 5, 2003
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions
A Chanan-Khan, J Szebeni, S Savay, et al.
Page
of 43